AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Henkel AG & Co. KGaA engages in the production, sale, and distribution of home and beauty care products. The firm also provides adhesive technology solutions. It operates through the following segments: Adhesive Technologies, Beauty Care, and Laundry and Home Care. The Adhesive Technologies segment sells adhesives, sealants, and functional coatings for consumers, craftsmen, and industrial applications. The Beauty Care segment comprises products in the fields of hair colorants, hair styling, hair care, toiletries, skin care, and oral hygiene. The Laundry and Home Care segment offers heavy-duty and specialty detergents, fabric softeners, laundry-performance enhancers, other fabric-care products, hand and automatic dishwashing products, bathroom cleaners, including household, glass, and specialty cleaners. The company was founded by Fritz Henkel on September 26, 1876 and is headquartered in Dusseldorf, Germany.

RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden.

Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. Their pioneering research is based on a strong heritage, stemming from in-house knowledge and their desire to strive for excellence. Their drug discovery efforts are based on selecting specific nuclear receptors as targets and utilizing rational drug design to optimize their drug candidates. This strong skill base associated to their scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities, have allowed us to build a solid scientific platform enabling us to discover and develop their drug candidates and diagnostic tools. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over the years. Today, he sits as chair of the Scientific Advisory Board, lending decades of experience and essential know-how, supporting their role as an innovative leader in the discovery of solutions for the metabolic field.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Reliant Pharmaceuticals provides cardiovascular pharmaceutical products. It is engaged in the sale and marketing of these products. Its product portfolio includes Axid, a nizatidin; InnoPran XL and DynaCirc CR for the treatment of hypertension; Omacor to reduce high triglycerides; and Rythmol SR. It provides products for the treatment of elevated cholesterol and triglycerides, acid reflux disease, and prevention of coronary complications in patients with coronary heart disease. It distributes its products to physicians engaged in primary care, cardiovascular, and specialized medical areas. Reliant Pharmaceuticals was established in 1999, headquartered in Liberty Corner, New Jersey.

Suzhou Yasheng Pharmaceutical Co., Ltd., established on 2016-06-01, The business scope includes the production of targeted drugs,R & D and sales,and provide technical services,technical consulting;Self-operated above-mentioned goods,Import and export business of technology and services,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;investment management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Synchroneuron, Inc. develops therapies for tardive dyskinesia (TD) and other neuropsychiatric disorders. It offers a novel treatment for movement disorders, utilizing a drug with simultaneous effects on excitatory and inhibitory neurotransmission. The company was founded by Kei-Lai L. Fong, William D. Kerns, Marc R. Cote and Barry S. Fogel in 2011 and is headquartered in Newton, MA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.